Individualizing Treatment Approaches in MPN

EP. 1: An Overview of Myeloproliferative Neoplasms

February 26th 2021

Srdan Verstovsek, MD, PhD, provides an overview of the similarities and differences between myeloproliferative neoplasms, including polycythemia vera, myelofibrosis, and essential thrombocythemia.

EP. 2: Diagnosis and Evaluation in Polycythemia Vera

March 3rd 2021

Evaluating treatment, diagnostic criteria, and risk-assessment tools in polycythemia vera.

EP. 3: Therapeutic Considerations in Polycythemia Vera

March 3rd 2021

Key opinion leaders discuss treatment goals, considerations, and guideline recommendations for patients with low- or high-risk polycythemia vera.

EP. 4: PV Progression and Guideline-Directed Management

March 10th 2021

Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.

EP. 5: Polycythemia Vera: An Update on Clinical Trials

March 10th 2021

Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.

EP. 6: Real-World Use of Ruxolitinib in Polycythemia Vera

March 17th 2021

Experts give real-world insight in using ruxolitinib in patients with polycythemia vera.

EP. 7: Emerging Therapeutic Options in Polycythemia Vera

March 17th 2021

What to look forward to in the polycythemia vera space, including new clinical trials.

EP. 8: Goals in Treating Low-Risk Primary Myelofibrosis

March 24th 2021

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic.

EP. 9: Risk, Prognosis, and Nontransplant Options in Primary Myelofibrosis

March 24th 2021

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

EP. 10: A Look at Fedratinib and the JAKARTA Trials

March 31st 2021

Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice.